BioXcel Therapeutics (BTAI) Reports Q2 Loss of $1.06/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 14, 2020 7:00 AM EDTSERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (NDA) submission to U.S. Food and Drug Administration (FDA) planned for Q1 2021
Initiating the third dose cohort, 90 mcg, of the TRANQUILITY trial in elderly dementia patients
Initiated a separate efficacy cohort in the Phase 2 trial of BXCL701 in combination with pembrolizumab (KEYTRUDA®) to include patients with castrate-resistant prostate cancer (CRPC)
Strengthened balance sheet through follow-on offering raising approximately $200 million in gross proceeds
Company... More
